PMID- 20207176
OWN - NLM
STAT- MEDLINE
DCOM- 20121130
LR  - 20211203
IS  - 1873-2496 (Electronic)
IS  - 1078-1439 (Linking)
VI  - 30
IP  - 4
DP  - 2012 Jul-Aug
TI  - mTOR pathway inhibition in renal cell carcinoma.
PG  - 356-61
LID - 10.1016/j.urolonc.2009.11.008 [doi]
AB  - Renal cell carcinoma therapy has changed in a very significant way in the last 
      few years. Up to 5 new agents have been developed, improving the results 
      previously achieved with cytokine therapy. Bevacizumab, sorafenib, sunitinib, 
      temsirolimus, and everolimus are now part of the therapeutic arsenal for this 
      illness. Particularly, this has been the first tumoral type in which inhibition 
      of mammalian target of rapamycin (mTOR) has proved its efficacy in phase III 
      trials, either as first-line therapy for poor prognosis patients (temsirolimus, 
      CCI-779) or as second-line therapy after failure of tyrosine-kinase inhibitors 
      (everolimus, RAD001). In this paper, we review the basis for mTOR inhibition in 
      RCC, and discuss the results of the trials involving temsirolimus and everolimus 
      for the treatment of this disease.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Pinto Marin, Alvaro
AU  - Pinto Marin A
AD  - Medical Oncology Department, University Hospital La Paz, Madrid, Spain. 
      alvaro_pinto_marin@hotmail.com
FAU - Redondo Sanchez, Andres
AU  - Redondo Sanchez A
FAU - Espinosa Arranz, Enrique
AU  - Espinosa Arranz E
FAU - Zamora Aunon, Pilar
AU  - Zamora Aunon P
FAU - Castelo Fernandez, Beatriz
AU  - Castelo Fernandez B
FAU - Gonzalez Baron, Manuel
AU  - Gonzalez Baron M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100305
PL  - United States
TA  - Urol Oncol
JT  - Urologic oncology
JID - 9805460
RN  - 0 (Protein Kinase Inhibitors)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Carcinoma, Renal Cell/drug therapy/*enzymology
MH  - Clinical Trials, Phase III as Topic
MH  - Everolimus
MH  - Humans
MH  - Kidney Neoplasms/drug therapy/*enzymology
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - *Signal Transduction
MH  - Sirolimus/analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
MH  - Treatment Outcome
EDAT- 2010/03/09 06:00
MHDA- 2012/12/10 06:00
CRDT- 2010/03/09 06:00
PHST- 2009/09/28 00:00 [received]
PHST- 2009/11/09 00:00 [revised]
PHST- 2009/11/10 00:00 [accepted]
PHST- 2010/03/09 06:00 [entrez]
PHST- 2010/03/09 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1078-1439(09)00361-5 [pii]
AID - 10.1016/j.urolonc.2009.11.008 [doi]
PST - ppublish
SO  - Urol Oncol. 2012 Jul-Aug;30(4):356-61. doi: 10.1016/j.urolonc.2009.11.008. Epub 
      2010 Mar 5.